Quinazolinones Derivatives for Treatment of Non-Alcoholic Fatty Liver Disease, Preparation and Use Thereof

1. The compounds are capable of modulating COP1 Ubiquitin Ligase enzyme through stabilization in hepatocytes.
2. The compounds can reduce the level of triglycerides in hepatocytes.
3. The compounds can be used in a clinical application for treating conditions involving Non-Alcoholic Fatty Liver Disease (NAFLD).

The invention relates to the preparation of new compounds in free form or in an acceptable salt form for modulation of Ubiquitin Ligase COP1 through its stabilization as a potential therapeutic target for Non-Alcoholic Fatty Liver Disease (NAFLD). Some of the synthesized molecules are capable of increasing the level of adipose triglyceride lipase (ATGL) through modulation of Ubiquitin Ligase COP1 through its stabilization as a potential therapeutic target.

The compounds can be used in a clinical application for treating conditions involving Non-Alcoholic Fatty Liver Disease (NAFLD).